Under the agreement, Vital Life will be responsible for product marketing and promotion, as well as local regulatory issues, supported by the expertise from Scandinavian Clinical Nutrition (SCN).
According to the company, the new lens offers an enhanced aspheric optic that improves image quality and increases contrast sensitivity in cataract surgery patients with astigmatism. The lens
Mr Nguyen joins the company’s senior management team and will be primarily responsible for managing the financial operations of the company. Mr Nguyen was formerly a part of
The Phase III registration program for DM-5689 in menopausal hot flashes includes two randomized, double-blind, placebo-controlled studies of approximately 540 patients per study. The treatment duration of the
The trial included four groups of 10 subjects each to assess the safety and tolerability of escalating doses of RGN-352 injected daily into the blood stream over a
The company has also announced that Joel Fleishman will retire from the board in May 2009. For the past six years Mr Sununu served as a US senator
The payment to Power Medical Interventions (PMI) was made in connection with the license and development agreement signed in September 2008 and is related to a novel surgical
Dr Fuchs will replace longtime BioMarin chief medical officer, Emil Kakkis. Dr Fuchs most recently served as executive vice president and chief medical officer of Onyx Pharmaceuticals. Dr
Sigal, the company’s executive vice president, chief scientific officer and president, research & development, oversees the company’s research, discovery, and development functions. Huet was promoted to executive vice
He will continue to report to James M. Cornelius, chairman and chief executive officer. “Lamberto’s leadership has been an integral part of our recent global commercial success, and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.